Cargando…

Timing of Adjuvant Chemoradiation in pT1-3N1-2 or pT4aN1 Esophageal Squamous Cell Carcinoma After R0 Esophagectomy

INTRODUCTION: Postoperative adjuvant radiation therapy (RT) and chemotherapy (aCRT) have been supposed to improve prognosis and outcomes in patients with node-positive thoracic esophageal squamous cell carcinoma (TESCC). Our aim was to analyze the impacts of interval between surgery and aCRT on prog...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Leilei, Zhang, Zhenshan, Li, Shuo, Ke, Linping, Yu, Jinming, Meng, Xue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603416/
https://www.ncbi.nlm.nih.gov/pubmed/33149667
http://dx.doi.org/10.2147/CMAR.S276426
_version_ 1783603914742956032
author Wu, Leilei
Zhang, Zhenshan
Li, Shuo
Ke, Linping
Yu, Jinming
Meng, Xue
author_facet Wu, Leilei
Zhang, Zhenshan
Li, Shuo
Ke, Linping
Yu, Jinming
Meng, Xue
author_sort Wu, Leilei
collection PubMed
description INTRODUCTION: Postoperative adjuvant radiation therapy (RT) and chemotherapy (aCRT) have been supposed to improve prognosis and outcomes in patients with node-positive thoracic esophageal squamous cell carcinoma (TESCC). Our aim was to analyze the impacts of interval between surgery and aCRT on prognosis, determining the optimal time interval. METHODS: We retrospectively reviewed 520 patients with TESCC between 2007 and 2015 treated with aCRT following radical esophagectomy without neoadjuvant chemotherapy and RT. These patients underwent RT (50–60 Gy) combined with 2–6 cycles chemotherapy after surgery. The time intervals were from 17 days to 145 days and divided into three groups: short interval group (≤28 days, S-Int group), medial interval group (≥29 and ≤ 56 days, M-Int group) and long interval group (≥57 days, L-Int group). RESULTS: Median follow-up was 35.6 months and the 3-, 5-year survival rates and median survival were 49.5%, 36.6% and 35.9 months. The duration of postoperative interval was a predictor of survival outcomes. The median survival and 5-year survival rates in S-Int, M-Int and L-Int groups were 23.6 (32.1%), 44.2 (43.3%) and 32.0 (31.5%) months (P=0.007). The difference was statistically significant between the M-Int and S-Int or L-Int group but was not between the S-Int and L-Int group. Besides, toxic reactions including early, late and adverse events (grade ≥3) in M-Int group were significantly less than S-Int and show no significant differences with L-Int group. CONCLUSION: The optimal time interval was from 29 days to 56 days (5–8 weeks) both in terms of survival outcomes and toxic reactions.
format Online
Article
Text
id pubmed-7603416
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-76034162020-11-03 Timing of Adjuvant Chemoradiation in pT1-3N1-2 or pT4aN1 Esophageal Squamous Cell Carcinoma After R0 Esophagectomy Wu, Leilei Zhang, Zhenshan Li, Shuo Ke, Linping Yu, Jinming Meng, Xue Cancer Manag Res Original Research INTRODUCTION: Postoperative adjuvant radiation therapy (RT) and chemotherapy (aCRT) have been supposed to improve prognosis and outcomes in patients with node-positive thoracic esophageal squamous cell carcinoma (TESCC). Our aim was to analyze the impacts of interval between surgery and aCRT on prognosis, determining the optimal time interval. METHODS: We retrospectively reviewed 520 patients with TESCC between 2007 and 2015 treated with aCRT following radical esophagectomy without neoadjuvant chemotherapy and RT. These patients underwent RT (50–60 Gy) combined with 2–6 cycles chemotherapy after surgery. The time intervals were from 17 days to 145 days and divided into three groups: short interval group (≤28 days, S-Int group), medial interval group (≥29 and ≤ 56 days, M-Int group) and long interval group (≥57 days, L-Int group). RESULTS: Median follow-up was 35.6 months and the 3-, 5-year survival rates and median survival were 49.5%, 36.6% and 35.9 months. The duration of postoperative interval was a predictor of survival outcomes. The median survival and 5-year survival rates in S-Int, M-Int and L-Int groups were 23.6 (32.1%), 44.2 (43.3%) and 32.0 (31.5%) months (P=0.007). The difference was statistically significant between the M-Int and S-Int or L-Int group but was not between the S-Int and L-Int group. Besides, toxic reactions including early, late and adverse events (grade ≥3) in M-Int group were significantly less than S-Int and show no significant differences with L-Int group. CONCLUSION: The optimal time interval was from 29 days to 56 days (5–8 weeks) both in terms of survival outcomes and toxic reactions. Dove 2020-10-27 /pmc/articles/PMC7603416/ /pubmed/33149667 http://dx.doi.org/10.2147/CMAR.S276426 Text en © 2020 Wu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Wu, Leilei
Zhang, Zhenshan
Li, Shuo
Ke, Linping
Yu, Jinming
Meng, Xue
Timing of Adjuvant Chemoradiation in pT1-3N1-2 or pT4aN1 Esophageal Squamous Cell Carcinoma After R0 Esophagectomy
title Timing of Adjuvant Chemoradiation in pT1-3N1-2 or pT4aN1 Esophageal Squamous Cell Carcinoma After R0 Esophagectomy
title_full Timing of Adjuvant Chemoradiation in pT1-3N1-2 or pT4aN1 Esophageal Squamous Cell Carcinoma After R0 Esophagectomy
title_fullStr Timing of Adjuvant Chemoradiation in pT1-3N1-2 or pT4aN1 Esophageal Squamous Cell Carcinoma After R0 Esophagectomy
title_full_unstemmed Timing of Adjuvant Chemoradiation in pT1-3N1-2 or pT4aN1 Esophageal Squamous Cell Carcinoma After R0 Esophagectomy
title_short Timing of Adjuvant Chemoradiation in pT1-3N1-2 or pT4aN1 Esophageal Squamous Cell Carcinoma After R0 Esophagectomy
title_sort timing of adjuvant chemoradiation in pt1-3n1-2 or pt4an1 esophageal squamous cell carcinoma after r0 esophagectomy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603416/
https://www.ncbi.nlm.nih.gov/pubmed/33149667
http://dx.doi.org/10.2147/CMAR.S276426
work_keys_str_mv AT wuleilei timingofadjuvantchemoradiationinpt13n12orpt4an1esophagealsquamouscellcarcinomaafterr0esophagectomy
AT zhangzhenshan timingofadjuvantchemoradiationinpt13n12orpt4an1esophagealsquamouscellcarcinomaafterr0esophagectomy
AT lishuo timingofadjuvantchemoradiationinpt13n12orpt4an1esophagealsquamouscellcarcinomaafterr0esophagectomy
AT kelinping timingofadjuvantchemoradiationinpt13n12orpt4an1esophagealsquamouscellcarcinomaafterr0esophagectomy
AT yujinming timingofadjuvantchemoradiationinpt13n12orpt4an1esophagealsquamouscellcarcinomaafterr0esophagectomy
AT mengxue timingofadjuvantchemoradiationinpt13n12orpt4an1esophagealsquamouscellcarcinomaafterr0esophagectomy